0.19毫克氟轻松醋酸酯玻璃体内植入剂治疗糖尿病性黄斑水肿的三年安全性与有效性:PALADIN研究
PALADIN是一项为期3年的4期非随机开放标签观察性研究,纳入既往接受糖皮质激素治疗且眼压无临床显著升高的糖尿病性黄斑水肿(DME)患者(202眼/159例)。36个月时,研究眼黄斑中心亚区厚度平均变化-60.69微米(P<0.0001),最佳矫正视力平均变化+3.61个字母(P=0.0222);治疗频率中位数从植入前3.4次/年降至植入后1次/年,治疗负担降低70.5%。
要点
- 36个月时研究眼黄斑中心亚区厚度平均变化-60.69微米(P<0.0001),最佳矫正视力平均变化+3.61个字母(P=0.0222)。
- 治疗频率中位数从植入前36个月的3.4次/年降至植入后36个月的1次/年,治疗负担降低70.5%。
- 眼压升高至超过30毫米汞柱见于10.89%的眼,眼压相关手术率为2.97%,其中1.49%归因于激素使用。
核心结论
- 在DME患者中,0.19毫克氟轻松醋酸酯植入剂相比既往治疗改善了视力结局并降低了治疗负担,同时保持了良好的安全性特征。
研究设计与样本
- 为期3年的4期非随机开放标签观察性研究,纳入既往接受糖皮质激素治疗且眼压无临床显著升高的DME患者,全部眼n=202眼(159例患者),完成36个月随访n=94眼。
- 患者基线接受0.19毫克氟轻松醋酸酯玻璃体内植入,随后观察安全性、视力、解剖及治疗负担相关结局至36个月。
主要发现
- 36个月时研究眼黄斑中心亚区厚度平均变化-60.69微米(P<0.0001),最佳矫正视力平均变化+3.61个字母(P=0.0222),均与基线相比。
- 总体治疗频率中位数从植入前36个月的3.4次/年降至植入后36个月的1次/年,治疗负担降低70.5%。
- 完成36个月治疗的组(n=94眼)中,25.53%的眼至36个月保持无需补救治疗。
- 研究期间平均眼压保持稳定,眼压升高至超过30毫米汞柱见于10.89%的眼。
- 眼压相关手术率为2.97%,其中1.49%归因于激素使用(对比主要归因于新生血管性青光眼的手术)。
关键数值与推荐
- 激素激发试验后眼压反应<25毫米汞柱预测96.92%的眼在末次访视时对0.19毫克氟轻松醋酸酯植入剂有相似结局。
- 发生的眼压升高可通过标准治疗管理(n=202眼)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (Iluvien; Alimera Sciences, Inc) in patients with diabetic macular edema (DME). DESIGN: Three-year, phase 4, nonrandomized, open-label observational study. PARTICIPANTS: Patients with DME who previously received corticosteroid treatment without a clinically significant rise in intraocular pressure (IOP; all eyes, n = 202 eyes of 159 patients; 36-month completion, n = 94 eyes). METHODS: A prospective, observational study in which patients received a 0.19-mg FAc intravitreal implant at baseline and then were observed for safety-, visual-, anatomic-, and treatment burden-related outcomes for up to 36 months. MAIN OUTCOME MEASURES: Primary safety outcomes included changes in IOP and interventions to manage IOP elevations. Secondary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and adjunctive DME treatment frequency RESULTS: At 36 months after FAc implantation, study eyes showed a mean CST change of -60.69 μm (P < 0.0001) and a mean BCVA change of +3.61 letters (P = 0.0222) compared with baseline. Overall median treatment frequency decreased from 3.4 treatments/year in the 36 months before FAc implantation to 1 treatment/year in the 36 months after FAc implant, a treatment burden reduction of 70.5%. Furthermore, among the group that completed 36 months of treatment (n = 94 eyes), 25.53% of eyes remained rescue free through 36 months. Mean IOP remained stable throughout the study, and IOP increases to more than 30 mmHg occurred in 10.89% of eyes. Intraocular pressure-related procedures were infrequent, with a surgical rate of 2.97%, with 1.49% attributable to steroid use (vs. surgeries attributable primarily to neovascular glaucoma). In addition, an IOP response of < 25 mmHg after the steroid challenge predicted that 96.92% of eyes would have a similar outcome to 0.19-mg FAc implant at the last visit. Intraocular pressure increases that did occur were manageable with standard treatments (n = 202 eyes). CONCLUSIONS: In patients with DME, the 0.19-mg FAc implant provided improved visual outcomes and reduced treatment burden compared with previous treatments while maintaining a favorable safety profile.
引用
- Singer MA, Sheth V, Mansour SE, et al. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study. Ophthalmology. 2022. PMID: 35063472. doi:10.1016/j.ophtha.2022.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。